NIFTY 50 23165.35 ▼ (0.77%)
NIFTY NEXT 50 63924.5 ▼ (1.81%)
NIFTY 100 23817.25 ▼ (0.96%)
NIFTY MIDCAP 100 54193.05 ▼ (1.66%)
NIFTY SMALLCAP 100 17570.85 ▼ (1.64%)
NIFTY SMALLCAP 250 16580.1 ▼ (1.55%)
NIFTY MIDCAP SELECT 12101.6 ▼ (2.06%)
NIFTY TOTAL MARKET 12167.55 ▼ (1.11%)
NIFTY BANK 48704.6 ▼ (1.31%)
SENSEX 76326.87 ▼ (0.97%)
BSE BANKEX 55243.59 ▼ (1.41%)

Godavari Drugs : Q4 2024 Financial Quarterly Report : YoY Sales Up 3.4 %, QoQ Down 10.37 %

July 3, 2024July 3, 2024| adminadmin| 0 Comments| 5:05 pm
Image is loading
Categories:

Share the post "Godavari Drugs : Q4 2024 Financial Quarterly Report : YoY Sales Up 3.4 %, QoQ Down 10.37 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 3.4 % in the past year, decrease in net sales/revenue by -10.37 %.
  • Income over the Year and quarter: There has been decline in other income over the past year which is -31.25 %, Marginal increase in other income during this quarter, up by 120%.
  • Profit over the Year and quarter: Significant improvement in profitability for Godavari Drugs Ltd.. Notable increase of 100 % in net profit Year to Year, Godavari Drugs Ltd.’s profitability increased by 118.02 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 99.44 % Year to Year. EPS increased by 117.9 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Godavari Drugs Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 37.37 Cr Rs. 43.111 Cr Rs. 38.64 Cr -10.37 % + 3.4 %
Expenses Rs. 34.69 Cr Rs. 39.59 Cr Rs. 34.17 Cr -13.69 % -1.5 %
Operating Profit Rs. 2.68 Cr Rs. 3.52 Cr Rs. 4.47 Cr + 26.99 % + 66.79 %
OPM % 7.17 % 8.16 % 11.57 % + 3.41 % + 4.4 %
Other Income Rs. 0.16 Cr Rs. 0.05 Cr Rs. 0.11 Cr + 120 % -31.25 %
Interest Rs. 1.03 Cr Rs. 1.28 Cr Rs. 1.23 Cr -3.91 % + 19.42 %
Depreciation Rs. 0.5 Cr Rs. 0.5 Cr Rs. 0.53 Cr + 6 % + 6 %
Profit before tax Rs. 1.31 Cr Rs. 1.79 Cr Rs. 2.82 Cr + 57.54 % + 115.27 %
Tax % 13.79 % 29.87 % 4.55 % -25.32 % -9.24 %
Net Profit Rs. 1.33 Cr Rs. 1.22 Cr Rs. 2.66 Cr + 118.03 % + 100 %
EPS in Rs Rs. 1.77 Rs. 1.62 Rs. 3.53 + 117.9 % + 99.44 %


Today, we’re looking at Godavari Drugs Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 3.4 %. However, it did see a marginal slip of -10.37 % from the previous quarter. Expenses decreased slightly by -13.69 % quarter-on-quarter, aligning with the annual decline of -1.5 %. Operating profit, while up 66.79 % compared to last year, faced a quarter-on-quarter increase of 26.99 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 4.4 %, but an expansion of 3.41 % sequentially. Other income rose by 120 % compared to the last quarter, despite an annual decline of -31.25 %. Interest expenses dropped significantly by -3.91 % from the previous quarter, yet the year-over-year increase remains at a moderate 19.42 %. Depreciation costs climbed by 6 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 6 %. Profit before tax grew annually by 115.27 % but saw an increase from the preceding quarter by 57.54 %.
Tax expenses as a percentage of profits decreased slightly by -9.24 % compared to last year, with a more notable quarter-on-quarter decrease of -25.32 %. Net profit rose by 100 % year-on-year but experienced a 118.03 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 99.44 % but a quarterly rise of 117.9 %. In summary, Godavari Drugs Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 37.37 Cr Rs. 43.111 Cr Rs. 38.64 Cr -10.37 % + 3.4 %
Expenses Rs. 34.69 Cr Rs. 39.59 Cr Rs. 34.17 Cr -13.69 % -1.5 %
Operating Profit Rs. 2.68 Cr Rs. 3.52 Cr Rs. 4.47 Cr + 26.99 % + 66.79 %
Net Profit Rs. 1.33 Cr Rs. 1.22 Cr Rs. 2.66 Cr + 118.03 % + 100 %
EPS in Rs Rs. 1.77 Rs. 1.62 Rs. 3.53 + 117.9 % + 99.44 %


In reviewing Godavari Drugs Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 3.4 % year-on-year growth, although there was a slight dip of -10.37 % from the previous quarter. Expenses decreased by -1.5 % compared to the previous year, with a decrease of -13.69 % quarter-on-quarter. Operating Profit surged by 66.79 % annually, and saw a 26.99 % increase from the last quarter.
Net Profit showed yearly increase of 100 %, and experienced a 118.03 % increase from the previous quarter. Earnings Per Share (EPS) rose by 99.44 % annually, however rose by 117.9 % compared to the last quarter. In essence, while Godavari Drugs Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Godavari Drugs “]

Related Post